Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Massimo Gentile, Tait D. Shanafelt, Francesca Romana Mauro, Gianluigi Reda, Davide Rossi, Luca Laurenti, Maria Ilaria Del Principe, Giovanna Cutrona, Ilaria Angeletti, Marta Coscia, Yair Herishanu, Annalisa Chiarenza, Stefano Molica, Stefania Ciolli, Neta Goldschmidt, Francesco Angrilli, Annamaria Giordano, Angela Rago, Osnat Bairey, Giovanni TripepiKari G. Chaffee, Sameer A Parikh, Ernesto Vigna, Katja Zirlik, Lev Shvidel, Idanna Innocenti, Anna Grazia Recchia, Francesco Di Raimondo, Giovanni Del Poeta, Agostino Cortelezzi, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Neil Elliot Kay, Aaron Polliack, Robin Foà, Fortunato Morabito

Research output: Contribution to journalLetter

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)703-706
Number of pages4
JournalEuropean Journal of Haematology
Volume101
Issue number5
DOIs
StatePublished - Nov 1 2018

Keywords

  • chemo-immunotherapy
  • chronic lymphocytic leukemia
  • CLL-IPI
  • PFS
  • prognosis
  • progression-free survival

ASJC Scopus subject areas

  • Hematology

Cite this

Gentile, M., Shanafelt, T. D., Mauro, F. R., Reda, G., Rossi, D., Laurenti, L., Del Principe, M. I., Cutrona, G., Angeletti, I., Coscia, M., Herishanu, Y., Chiarenza, A., Molica, S., Ciolli, S., Goldschmidt, N., Angrilli, F., Giordano, A., Rago, A., Bairey, O., ... Morabito, F. (2018). Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. European Journal of Haematology, 101(5), 703-706. https://doi.org/10.1111/ejh.13149